Vazquez-Bourgon, JavierOrtiz-Garcia-de-la-Foz, VictorGomez-Revuelta, MarcosMayoral-van-Son, JacquelineJuncal-Ruiz, MariaGarrido-Torres, NathaliaCrespo-Facorro, Benedicto2023-05-032023-05-032022-04-29Vázquez-Bourgon J, Ortiz-García de la Foz V, Gómez-Revuelta M, Mayoral-van Son J, Juncal-Ruiz M, Garrido-Torres N, et al. Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. Int J Neuropsychopharmacol. 2022 Oct 25;25(10):795-806.http://hdl.handle.net/10668/19803Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. However, a longer period is necessary for a better assessment of the SGA´s metabolic profile. We aimed to compare the long-term (1-year) metabolic profile of these 2 antipsychotics on a sample of drug-naïve first episode-psychosis (FEP) patients. A total 188 drug-naïve patients, suffering from a first episode of non-affective psychosis (FEP), were randomly assigned to treatment with either aripiprazole or risperidone. Weight and glycemic/lipid parameters were recorded at baseline and after 1-year follow-up. We observed significant weight increments in both groups (9.2 kg for aripiprazole and 10.5 kg for risperidone) after 1 year of treatment. Despite this, weight and body mass index changes did not significantly differ between treatment groups (P > .05). Similarly, both treatment groups presented similar metabolic clinical impact with a comparable increase in the proportion of participants meeting criteria for metabolic disorders such as obesity or hypercholesterolemia, but not for metabolic syndrome (Δ9.2% vs Δ4.3%) or hypertriglyceridemia (Δ21.9% vs Δ8.0%), where aripiprazole showed worse outcomes than risperidone. This study shows that aripiprazole and risperidone share a similar long-term metabolic profile. After 1 year of antipsychotic treatment, drug-naïve FEP patients in both treatment groups presented a significant increase in weight and metabolic changes, leading to a greater prevalence of metabolic disorders.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Metabolismschizophreniasecond-generation antipsychotictreatment-naïveweight gainHumansAripiprazoleRisperidoneAntipsychotic AgentsPsychoses, Substance-InducedMetabolomeLipidsPsychotic Disordersresearch article35641112open accessTerapéuticaRisperidonaMetabolomaPacientesTrastornos psicóticosSíndrome metabólicoHipercolesterolemiaObesidadHipertrigliceridemia10.1093/ijnp/pyac0331469-5111PMC9593219https://doi.org/10.1093/ijnp/pyac033https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593219/pdf